Your browser doesn't support javascript.
loading
Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck.
Gastman, Brian R; Zager, Jonathan S; Messina, Jane L; Cook, Robert W; Covington, Kyle R; Middlebrook, Brooke; Gerami, Pedram; Wayne, Jeffrey D; Leachman, Sancy; Vetto, John T.
Affiliation
  • Gastman BR; Department of Plastic Surgery, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio.
  • Zager JS; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida.
  • Messina JL; Department of Anatomic Pathology, H. Lee Moffitt Cancer Center, Tampa, Florida.
  • Cook RW; Research & Development, Castle Biosciences, Inc., Friendswood, Texas.
  • Covington KR; Research & Development, Castle Biosciences, Inc., Friendswood, Texas.
  • Middlebrook B; Research & Development, Castle Biosciences, Inc., Friendswood, Texas.
  • Gerami P; Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Wayne JD; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Leachman S; Skin Cancer Institute, Northwestern University, Lurie Comprehensive Cancer Center, Chicago, Illinois.
  • Vetto JT; Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Head Neck ; 41(4): 871-879, 2019 04.
Article in En | MEDLINE | ID: mdl-30694001
ABSTRACT

BACKGROUND:

We report the performance of a gene expression profile test to classify the recurrence risk of cutaneous melanoma tumors of the head and neck as low-risk Class 1 or high-risk Class 2.

METHODS:

Of note, 157 primary head and neck cutaneous melanoma tumors were identified. Survival analyses were performed using Kaplan-Meier and Cox methods.

RESULTS:

Gene expression profile class and node status stratified tumors into significantly different 5-year survival groups by Kaplan-Meier method (P < .0001 for all end points), and both were independent predictors of recurrence in multivariate analysis. Overall, 74% of distant metastases and 88% of melanoma-specific deaths had Class 2 risk.

CONCLUSION:

The gene expression profile test identifies cases at increased risk for metastasis and death independent of a clinically or pathologically negative nodal status, suggesting that incorporation of this molecular tool could improve clinical management of patients with head and neck cutaneous melanoma, especially in those with a negative sentinel lymph node biopsy.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Gene Expression Profiling / Head and Neck Neoplasms / Lymph Nodes / Melanoma Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Head Neck Journal subject: NEOPLASIAS Year: 2019 Document type: Article Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Gene Expression Profiling / Head and Neck Neoplasms / Lymph Nodes / Melanoma Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Head Neck Journal subject: NEOPLASIAS Year: 2019 Document type: Article Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA